Allogran-R®A highly consistent, polycrystalline and porous calcium phosphate bone substitute that provides an osteoconductive scaffold for use in trauma and spine.
Synthetic bone substitute
Allogran-R is a fully absorbable β tri-calcium phosphate. Its irregular particles, when combined with saline or blood, assume a cohesive regenerative matrix for the treatment of trauma, spine and non-unions:
- Engineered porosity for complete absorption in 6–12 months
- No risk of disease transmission
- Elimination of donor site morbidity
Absorption process in vivo
|STAGE 1||Physiochemical dissolution of individual particles|
|STAGE 2||Biological absorption by osteoclasts|
Electron micrograph showing microporous structure of Allogran-R granules.
Engineered for absorption
Biocomposites, through its proprietary process, has engineered a multiporous granular matrix with outstanding biocompatibility, which is truly absorbable through the process of dissolution and cell mediation.
|Bio-replaceable implant scaffold||Inter-granular macroporosity > 100 µm (vascularisation)|
|Osteoconductive||Polycrystalline microporosity < 10 µm for early cell attachment|
|Bioactive||Osteoconductive matrix promoting osteoblast proliferation|
|Biocompatible||High purity β tri-calcium phosphate with controlled chemistry|
|Total resorption (absorption)||Stoichiometric calcium to phosphorus ratio 1.5|
Micrograph showing osteoblasts proliferating on the micro-porous surface of Allogran-R at 21 days in vitro.
Absorption of Allogran-R1
a) Supracondylar fracture of the left femur 66-year-old female
b) 3 months post-operatively after fracture plated and packed with Allogran-R
c) 6 months post-operatively
d) 10 months post-operatively, radiographic evidence of new bone with advanced absorption of Allogran-R
Irregular granules combine to form a multiporous matrix.
- Average particle size of 2.0 mm
To fill a bone defect caused by:
- Delayed union or non-union
- Removal of tumour or cyst
|Chemical||Ca3(PO4)2 (Conforms to ASTM F1088-04a)|
|Physical||Irregular granule ~ 2000 µm|
|Crystallinity||>95% β tri-calcium phosphate|
|Matrix structure||>200 µm macropores, < 10 µm micropores|
|POT SIZE||ORDER CODES|
Supplied sterile, ready
for immediate use
Use of Allogran-R in the treatment of intra-articular calcaneal fracture
Patient presented with: subtalar degenerative disease in the right foot, following an intra-articular calcaneal fracture.
Outcome: At 3 months post-operatively, the patient reported a reduction in pain. Radiographic examination indicated integration of the graft material with new bone formation at the fusion site. At 9 months post-operatively, the patient reported uneventful healing. Further radiographic examination indicated significant absorption of the graft material and effective radiographic fusion at the site.
Use of Allogran-R in the treatment of a supracondylar fracture of the left femur
Patient presented with: a supracondylar fracture of the left femur.
Outcome: At 3 months post-operatively, the fracture site was stable and the Allogran-R granules were evident. At 10 months post-operatively, there was radiographic evidence of new bone at the site with advanced absorption of the bone graft material.